In vivo demonstration of an active tumor pretargeting approach with peptide nucleic acid bioconjugates as complementary system† †Electronic supplementary information (ESI) available: Characterization of the PNAs used this study (Fig. S1–14), radio HPLC of [99mTc](Tc-Dpa)-(Cys-PEG10kDa)-PNA (Fig. S15), melting temperatures (TM) for three complementary 17-mer PNA systems (Table S1), melting curves of different PNAs (Fig. S16), radio HPLC of the [99mTc](Tc-Dpa)-(Cys-PEG10kDa)-PNA (original), in rat

• Published in: Chemical science (Cambridge) Vol. 6; no. 10; pp. 5601 - 5616
• Main Authors: Leonidova, Anna, Foerster, Christian, Zarschler, Kristof, Schubert, Maik, Pietzsch, Hans-Jürgen, Steinbach, Jörg, Bergmann, Ralf, Metzler-Nolte, Nils, Stephan, Holger, Gasser, Gilles
• Format: Journal Article
• Language: English
• Published: Royal Society of Chemistry 17.06.2015
• Subjects: Chemistry

The first successful application of a pretargeting approach using a PNA-modified epidermal growth factor receptor specific antibody and a complementary 99m Tc-labeled PNA is presented. A novel, promising strategy for cancer diagnosis and therapy is the use of a pretargeting approach. For this purpos...